These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8731790)

  • 21. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The significance of quantification of MDR1 and WT1 gene expression in acute myeloid leukemia].
    Xu B; Song XY; Li L; Xu WJ; Tang JH
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):221-4. PubMed ID: 18785507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
    Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
    Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: comparison of two monoclonal antibodies and three fluorescent dyes in three cells lines.
    Maynadie M; Lizard G; Solary E; Roignot P; Carli PM
    Anticancer Res; 1994; 14(6B):2605-9. PubMed ID: 7872688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flow cytometry evaluation of the multidrug-resistant phenotype with functional tests involving uptake of daunorubicin, Hoechst 33342, or rhodamine 123: a comparative study.
    Lizard G; Roignot P; Maynadie M; Lizard-Nacol S; Poupon MF; Bordes M
    Cancer Detect Prev; 1995; 19(6):527-34. PubMed ID: 8925522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
    Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
    Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression.
    Marie JP; Faussat-Suberville AM; Zhou D; Zittoun R
    Leukemia; 1993 Jun; 7(6):825-31. PubMed ID: 8099135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P; Urbánek V
    Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival.
    Pogliani EM; Carpenedo M; Miccolis I; Belotti D; Corneo GM
    Hematology; 2000; 5(5):359-67. PubMed ID: 27420927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of functional assay of multidrug resistance for prediction of chemotherapy outcomes in acute leukemia].
    Ye X; Tan H; Feng Y; Su H; Lai YY; Pang Y
    Ai Zheng; 2003 Aug; 22(8):856-60. PubMed ID: 12917035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
    te Boekhorst PA; de Leeuw K; Schoester M; Wittebol S; Nooter K; Hagemeijer A; Löwenberg B; Sonneveld P
    Blood; 1993 Nov; 82(10):3157-62. PubMed ID: 7693039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
    Xu WL; Shen HL; Ao ZF; Chen BA; Xia W; Gao F; Zhang YN
    Leuk Res; 2006 Apr; 30(4):407-13. PubMed ID: 16219352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of multidrug resistant phenotype by flow cytometry with monoclonal antibodies and functional tests.
    Lizard G; Maynadié M; Roignot P; Lizard-Nacol S; Poupon MF
    Bull Cancer; 1995 Mar; 82(3):211-7. PubMed ID: 7655150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy resistance in acute myeloid leukaemia.
    Sonneveld P; List AF
    Best Pract Res Clin Haematol; 2001 Mar; 14(1):211-33. PubMed ID: 11355932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
    Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
    Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.